Esophageal Cancer

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Approved for Some Patients with Advanced Esophageal CancerBookmark

Article from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes: 

In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.

Go to full article published by the National Cancer Institute.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Esophageal Cancer—An OverviewBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Esophageal carcinoma is the ninth most frequently diagnosed potentially lethal cancer worldwide, although there is great geographic variation in disease frequency and cell type of origin. This August 2019 treatise from Medscape illustrates all major aspects.

.

Blood-Based Screening Test May Aid in Detecting GI CancersBookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

In a First, Proton Therapy Bests Radiotherapy in an RCTBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial that compared proton beam therapy with standard radiotherapy for esophageal cancer, the two treatments were found to be virtually identical in terms of progression-free survival, overall survival, and quality of life.

Go to full news article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysisBookmark

Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

This meta-analysis found that minimally invasive surgery tops open esophagectomy for esophageal cancer.

Go to full paper published in Annals of Surgery.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (Attraction-3): A Multicentre, Randomised, Open-Label, Phase 3 TrialBookmark

Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

Go to full paper published in The Lancet.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Less Invasive Surgery Wins in Esophageal CancerBookmark

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

Minimally invasive surgery for esophageal cancer produces similar outcomes with fewer complications than open surgery. A reduction in pulmonary atelectasis may underlie these findings.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Esophageal Cancer Treatment (Adult) (PDQ®)–Patient VersionBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Esophageal cancer is common and difficult to treat; causation, classification and diagnosis are evolving. Read here a patient-friendly overview of the disease from the U.S. National Cancer Institute.

.

‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Trials Gone VirtualBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

These Underlying Conditions Make Coronavirus More Severe, and They’re Surprisingly CommonBookmark

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.